APA

Wykoff C. C., Brown D. M., Chen E., Major J. C., Croft D. E., Mariani A. & Wong T. P. (20130710). SAVE (Super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results. : Ophthalmic surgery, lasers & imaging retina.

Chicago

Wykoff Charles C, Brown David M, Chen Eric, Major James C, Croft Daniel E, Mariani Angeline and Wong Tien P. 20130710. SAVE (Super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results. : Ophthalmic surgery, lasers & imaging retina.

Harvard

Wykoff C. C., Brown D. M., Chen E., Major J. C., Croft D. E., Mariani A. and Wong T. P. (20130710). SAVE (Super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results. : Ophthalmic surgery, lasers & imaging retina.

MLA

Wykoff Charles C, Brown David M, Chen Eric, Major James C, Croft Daniel E, Mariani Angeline and Wong Tien P. SAVE (Super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results. : Ophthalmic surgery, lasers & imaging retina. 20130710.